Search

Your search keyword '"Hitchon, C."' showing total 205 results
Start Over Author "Hitchon, C."
205 results on '"Hitchon, C."'

2. OP0064 CHARACTERIZING PREVALENT NON-ARTICULAR PAIN AT EARLY RA DIAGNOSIS AND EVOLUTION OVER THE FIRST YEAR OF RA TREATMENT: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY

Author

Meng, C., primary, Lee, Y., additional, Schieir, O., additional, Valois, M. F., additional, Butler, M., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C. A., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bessette, L., additional, Pope, J., additional, Bartlett, S. J., additional, and Bykerk, V., additional

Published
2024
Full Text
View/download PDF

3. POS1047 STATIN USE ATTENUATES THE IMPACT OF SYSTEMIC INFLAMMATION ON ISCHEMIC CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Karpouzas, G., primary, Ormseth, S., additional, Van Riel, P., additional, Myasoedova, E., additional, González-Gay, M. Á., additional, Corrales Martinez, A., additional, Rantapää Dahlqvist, S., additional, Sfikakis, P. P., additional, Dessein, P., additional, Tsang, L., additional, Hitchon, C., additional, El-Gabalawy, H., additional, Pascual, V., additional, Contreras-Yáñez, I., additional, Colunga-Pedraza, I. J., additional, Galarza-Delgado, D. A., additional, Azpiri-Lopez, J. R., additional, Semb, A. G., additional, Rollefstad, S., additional, Misra, D. P., additional, Kitas, G., additional, and Hauge, E. M., additional

Published
2024
Full Text
View/download PDF

4. POS0030 METHOTREXATE USE ASSOCIATES WITH ISCHEMIC CARDIOVASCULAR RISK REDUCTION IN MALES BUT NOT FEMALES WITH RHEUMATOID ARTHRITIS

Author

Karpouzas, G., primary, Ormseth, S., additional, Van Riel, P., additional, Crowson, C. S., additional, Myasoedova, E., additional, Gabriel, S., additional, González-Gay, M. A., additional, Corrales, A., additional, Rantapää Dahlqvist, S., additional, Sfikakis, P., additional, Dessein, P., additional, Tsang, L., additional, Hitchon, C., additional, El-Gabalawy, H., additional, Pascual, V., additional, Colunga-Pedraza, I. J., additional, Galarza-Delgado, D. Á., additional, Azpiri-López, J. R., additional, Rollefstad, S., additional, Semb, A. G., additional, Misra, D. P., additional, Kitas, G., additional, and Hauge, E. M., additional

Published
2023
Full Text
View/download PDF

5. POS0471 SPECIFIC SYMPTOM CLUSTERS AT DIAGNOSIS SIGNAL A POORER EARLY RA PROGNOSIS: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT

Author

Bartlett, S. J., primary, Bingham, C. O., additional, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Pope, J., additional, Bessette, L., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Hazlewood, G., additional, Keystone, E., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

6. POS0458 HAVING MORE TENDER THAN SWOLLEN JOINTS IS ASSOCIATED WITH WORSE FUNCTION, PAIN INTERFERENCE, SOCIAL PARTICIPATION AND OTHER HR-QOL OUTCOMES IN THE FIRST YEAR FOLLOWING RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY

Author

Meng, C., primary, Lee, Y., additional, Schieir, O., additional, Valois, M. F., additional, Butler, M., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bessette, L., additional, Pope, J., additional, Bartlett, S. J., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

7. POS0034 BIOLOGIC USE REGULATES THE IMPACT OF INFLAMMATION ON ISCHEMIC CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS

Author

Karpouzas, G., primary, Ormseth, S., additional, Van Riel, P., additional, Myasoedova, E., additional, González-Gay, M. A., additional, Corrales, A., additional, Rantapää Dahlqvist, S., additional, Sfikakis, P., additional, Dessein, P., additional, Tsang, L., additional, Hitchon, C., additional, Pascual, V., additional, Colunga-Pedraza, I. J., additional, Galarza-Delgado, D. Á., additional, Azpiri-López, J. R., additional, Rollefstad, S., additional, Semb, A. G., additional, Misra, D. P., additional, Hauge, E. M., additional, and Kitas, G., additional

Published
2023
Full Text
View/download PDF

8. POS0584-HPR PROS AND DISEASE ACTIVITY IN YEAR PRIOR TO COVID PREDICT TRAJECTORIES OF DEPRESSION IN ADULTS WITH RA IN FIRST 2 YEARS OF PANDEMIC: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Pope, J., additional, Bessette, L., additional, Boire, G., additional, Hitchon, C., additional, Keystone, E., additional, Thorne, C., additional, Tin, D., additional, Hazlewood, G., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

10. OP0308-HPR MORE THAN HALF OF RA PATIENTS WITH A LIFETIME HISTORY OF MOOD DISORDERS WERE ANXIOUS AND DEPRESSED DURING THE COVID-19 PANDEMIC: RESULTS FROM THE CANADIAN EARLY COHORT (CATCH) STUDY

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Hazlewood, G., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Pope, J., additional, Keystone, E., additional, Bessette, L., additional, and Bykerk, V., additional

Published
2022
Full Text
View/download PDF

14. Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort

Author

Ellingwood, L., Schieir, O., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Keystone, E. C., Tin, D., Thorne, C., Bykerk, V. P., Pope, J. E., Baron, Murray, Bessette, Louis, Boire, Gilles, Bykerk, Vivian, Colmegna, Ines, Fallavollita, Sabrina, Haaland, Derek, Haraoui, Paul, Hazlewood, Glen, Hitchon, Carol, Jamal, Shahin, Joshi, Raman, Keystone, Ed, Nair, Bindu, Panopoulos, Peter, Pope, Janet, Rubin, Laurence, Thorne, Carter, Villeneuve, Edith, and Zummer, Michel

Subjects
medicine.medical_specialty, lcsh:Diseases of the musculoskeletal system, business.industry, Swollen joints, General Medicine, Early rheumatoid arthritis, Original Articles, Logistic regression, Clinical disease, medicine.disease, Joint pain, Internal medicine, Cohort, Medicine, Original Article, Palindromic rheumatism, lcsh:RC925-935, medicine.symptom, business, Early arthritis
Abstract

Background This multicenter incident cohort aimed to characterize how often early rheumatoid arthritis (ERA) patients self‐report episodic joint inflammation (palindromic rheumatism) preceding ERA diagnosis and which characteristics differentiate these patients from those without prior episodic symptoms. Methods Data were from patients with early confirmed or suspected RA (more than 6 weeks and less than 12 months) enrolled in the Canadian Early ArThritis CoHort (CATCH) between April 2017 to March 2018 who completed study case report forms assessing joint pain and swelling prior to ERA diagnosis. Chi‐square and t tests were used to compare characteristics of patients with and without self‐reported episodic joint inflammation prior to ERA diagnosis. Multivariable logistic regression was used to identify sociodemographic and clinical measures associated with past episodic joint inflammation around the time of ERA diagnosis. Results A total of 154 ERA patients were included; 66% were female, and mean (SD) age and RA symptom duration were 54 (15) years and 141 (118) days. Sixty‐five (42%) ERA patients reported a history of episodic joint pain and swelling, half of whom reported that these symptoms preceded ERA diagnosis by over 6 months. ERA patients with past episodic joint inflammation were more often female, had higher income, were seropositive, had more comorbidities, fewer swollen joints, and lower Clinical Disease Activity Index (CDAI) around the time of ERA diagnosis (P < 0.05). These associations remained significant in multivariable regression adjusting for other sociodemographic and RA clinical measures. Conclusion Almost half of ERA patients experienced episodic joint inflammation prior to ERA diagnosis. These patients were more often female, had higher income, and presented with milder disease activity at ERA diagnosis.

Published
2019

15. Validity of the Health Assessment Questionnaire Predicting All‐Cause Mortality in Early Rheumatoid Arthritis: Reply to three letters to the editor

Author

Fatima, Safoora, primary, Schieir, O., additional, Valois, M.F., additional, Bartlett, S.J., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E.C., additional, Tin, D., additional, Thorne, C., additional, Bykerk, V.P., additional, Pope, J.E., additional, and Investigators, CATCH, additional

Published
2021
Full Text
View/download PDF

16. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: An international audit

Author

Semb, A.G. Rollefstad, S. Ikdahl, E. Wibetoe, G. Sexton, J. Crowson, C. Van Riel, P. Kitas, G. Graham, I. Rantapää-Dahlqvist, S. Karpouzas, G.A. Myasoedova, E. Gonzalez-Gay, M.A. Sfikakis, P.P. Tektonidou, M.G.G. Lazarini, A. Vassilopoulos, D. Kuriya, B. Hitchon, C. Stoenoiu, M.S. Durez, P. Pascual-Ramos, V. Galarza-Delgado, D.A. Faggiano, P. Misra, D.P. Borg, A.A. Mu, R. Mirrakhimov, E.M. Gheta, D. Douglas, K. Agarwal, V. Myasoedova, S. Krougly, L. Valentinovna Popkova, T. TuchyÅ ová, A. Tomcik, M. Vrablik, M. Lastuvka, J. Horak, P. Medkova, H.K. Kerola, A.M.

Abstract

Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p

Published
2021

17. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit

Author

Semb, A.G., Rollefstad, S., Ikdahl, E., Wibetoe, G., Sexton, J., Crowson, C., Riel, P.L. van, Kitas, G., Graham, I., Rantapää-Dahlqvist, S., Karpouzas, G.A., Myasoedova, E., Gonzalez-Gay, M.A., Sfikakis, P.P., Tektonidou, M.G.G., Lazarini, A., Vassilopoulos, D., Kuriya, B., Hitchon, C., Stoenoiu, M.S., Durez, P., Pascual-Ramos, V., Galarza-Delgado, D.A., Faggiano, P., Misra, D.P., Borg, A.A., Mu, R., Mirrakhimov, E.M., Gheta, D., Douglas, K., Agarwal, V., Myasoedova, S., Krougly, L., Popkova, T. Valentinovna, Tuchyňová, A., Tomcik, M., Vrablik, M., Lastuvka, J., Horak, P., Medkova, H.K., Kerola, A.M., Semb, A.G., Rollefstad, S., Ikdahl, E., Wibetoe, G., Sexton, J., Crowson, C., Riel, P.L. van, Kitas, G., Graham, I., Rantapää-Dahlqvist, S., Karpouzas, G.A., Myasoedova, E., Gonzalez-Gay, M.A., Sfikakis, P.P., Tektonidou, M.G.G., Lazarini, A., Vassilopoulos, D., Kuriya, B., Hitchon, C., Stoenoiu, M.S., Durez, P., Pascual-Ramos, V., Galarza-Delgado, D.A., Faggiano, P., Misra, D.P., Borg, A.A., Mu, R., Mirrakhimov, E.M., Gheta, D., Douglas, K., Agarwal, V., Myasoedova, S., Krougly, L., Popkova, T. Valentinovna, Tuchyňová, A., Tomcik, M., Vrablik, M., Lastuvka, J., Horak, P., Medkova, H.K., and Kerola, A.M.

Abstract

Contains fulltext : 238631.pdf (Publisher’s version ) (Open Access), AIM: The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. METHODS: The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. RESULTS: The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. CONCLUSION: CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .

Published
2021

19. OP0262-HPR THE NEURO-QOL UPPER EXTREMITY FUNCTION SCALE: NEW OPPORTUNITIES TO MORE RELIABLY AND PRECISELY MEASURE SELF-REPORTED HAND FUNCTION AND SELF-CARE ACTIVITIES IN PEOPLE WITH RA

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Pope, J., additional, Keystone, E., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Bessette, L., additional, Hazlewood, G., additional, and Bykerk, V., additional

Published
2021
Full Text
View/download PDF

20. POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT

Author

Hadwen, B., primary, Stranges, S., additional, Klar, N., additional, Bindee, K., additional, Pope, J., additional, Bartlett, S. J., additional, Boire, G., additional, Bessette, L., additional, Hitchon, C., additional, Hazlewood, G., additional, Keystone, E., additional, Schieir, O., additional, Thorne, C., additional, Tin, D., additional, Valois, M. F., additional, Bykerk, V., additional, and Barra, L., additional

Published
2021
Full Text
View/download PDF

21. FRI0030 MORE THAN HALF OF NEWLY DIAGNOSED RA PATIENTS ARE NOT CONVINCED OF THE NECESSITY OF RA MEDICINES: ASSOCIATIONS WITH RA CHARACTERISTICS, SYMPTOMS, AND FUNCTION IN THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)

Author

Ta, V., primary, Schieir, O., additional, Valois, M. F., additional, Hazlewood, G., additional, Hitchon, C., additional, Bessette, L., additional, Tin, D., additional, Thorne, C., additional, Pope, J., additional, Boire, G., additional, Keystone, E., additional, Bykerk, V., additional, and Bartlett, S. J., additional

Published
2020
Full Text
View/download PDF

25. SAT0053 ESTIMATING REAL-WORLD UNMET NEEDS FOR REACHING REMISSION IN THE FIRST YEAR FOLLOWING EARLY RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)

Author

Schieir, O., primary, Bartlett, S. J., additional, Valois, M. F., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Pope, J., additional, Thorne, C., additional, Tin, D., additional, and Bykerk, V., additional

Published
2020
Full Text
View/download PDF

27. FRI0032 REGIONAL AND WIDESPREAD PATTERNS OF NON-ARTICULAR PAIN ARE COMMON AT RA DIAGNOSIS AND CONTRIBUTE TO POOR OUTCOMES AT 12 MONTHS: A PROSPECTIVE STUDY OF PAIN PATTERNS IN CANADIANS WITH RA

Author

Bykerk, V., primary, Schieir, O., additional, Valois, M. F., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Pope, J., additional, and Bartlett, S. J., additional

Published
2020
Full Text
View/download PDF

30. SAT0127 REAL-WORLD PREDICTORS OF STARTING DIFFERENT ADVANCED DMARD TREATMENTS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE INVESTIGATION FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) GROUP

Author

Weiler, M., primary, Schieir, O., additional, Valois, M. F., additional, Bartlett, S. J., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bykerk, V., additional, and Pope, J., additional

Published
2020
Full Text
View/download PDF

32. Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives, and Healthy Controls

Author

Koppejan, H., Trouw, L. A., Sokolove, J., Lahey, L. J., Huizinga, T. J. W., Smolik, I. A., Robinson, D. B., El‐Gabalawy, H. S., Toes, R. E. M., and Hitchon, C. A.

Subjects
Adult, Male, musculoskeletal diseases, Rheumatoid Arthritis, Middle Aged, Peptides, Cyclic, Arthritis, Rheumatoid, Rheumatoid Factor, Indians, North American, Citrulline, Humans, Female, skin and connective tissue diseases, Autoantibodies
Abstract

Objective Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies, including seropositivity for rheumatoid factor (RF) and anti–citrullinated protein antibodies (ACPAs). In addition, antibodies to carbamylated proteins (anti‐CarP) are present in patients with RA and are associated with joint damage. This study was undertaken to assess the presence of anti‐CarP antibodies in indigenous North Americans (First Nations [FN] populations) with RA compared to their at‐risk first‐degree relatives (FDRs) and healthy controls. Methods Anti‐CarP IgG and ACPAs (specifically, anti–cyclic citrullinated peptide [anti‐CCP] antibodies) were measured by enzyme‐linked immunosorbent assay in the sera of FN patients with RA (n = 95), their unaffected FDRs (n = 109), and healthy FN controls (n = 85). Antibodies to additional citrullinated peptides were measured using a multiplex ACPA array, and the number of peptides recognized was reported as an ACPA score. Groups were compared using the chi‐square test and Mann‐Whitney U test. Associations between RA and seropositivity for RF, ACPAs, and anti‐CarP antibodies were determined by logistic regression. Results Anti‐CarP antibodies were more frequent in FN patients with RA (44.3%) compared to FDRs (18.3%) and FN controls (4.7%) (both P

Published
2016

34. CARDIOVASCULAR RISK AGE AND VASCULAR AGE ESTIMATIONS IN PREDICTING CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS

Author

Wibetoe, G., Sexton, J., Ikdahl, E., Rollefstad, S., Kitas, G., van Riel, P., Gabriel, S., Kvien, T. K., Douglas, K., Sandoo, A., Arts, E. E., Wallberg-Jonsson, S., Dahlqvist, S. Rantapaa, Karpouzas, G., Dessein, P. H., Tsang, L., EI-Gabalawy, H., Hitchon, C. A., Pascual-Ramos, V., Contreas-Yanes, I., Sfikakis, P. P., Gonzalez-Gay, M. A., Colunga-Pedraz, I. J., Galarza-Delgado, D. A., Azpiri-Lopez, J. R., Crowson, C. S., Semb, A. G., and Rheumatology

Published
2018

35. CARDIOVASCULAR RISK AGE AND VASCULAR AGE ESTIMATIONS IN PREDICTING CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS

Author

Wibetoe, G. Sexton, J. Ikdahl, E. Rollefstad, S. Kitas, G. van Riel, P. Gabriel, S. Kvien, T. K. Douglas, K. and Sandoo, A. Arts, E. E. Wallberg-Jonsson, S. Dahlqvist, S. Rantapaa Karpouzas, G. Dessein, P. H. Tsang, L. and EI-Gabalawy, H. Hitchon, C. A. Pascual-Ramos, V. and Contreas-Yanes, I. Sfikakis, P. P. Gonzalez-Gay, M. A. and Colunga-Pedraz, I. J. Galarza-Delgado, D. A. Azpiri-Lopez, J. R. and Crowson, C. S. Semb, A. G.

Published
2018

36. Health Assessment Questionnaire at One Year Predicts All‐Cause Mortality in Patients With Early Rheumatoid Arthritis.

Author

Fatima, Safoora, Schieir, O., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Keystone, E. C., Tin, D., Thorne, C., Bykerk, V. P., Pope, J. E., Baron, Murray, Bessette, Louis, Boire, Gilles, Bykerk, Vivian, Colmegna, Ines, Fallavollita, Sabrina, and Haaland, Derek

Subjects
CONFIDENCE intervals, DISABILITY evaluation, QUESTIONNAIRES, RHEUMATOID arthritis, PROPORTIONAL hazards models, DESCRIPTIVE statistics
Abstract

Objective: Higher self‐reported disability (high Health Assessment Questionnaire [HAQ] score) has been associated with hospitalizations and mortality in established rheumatoid arthritis (RA), but associations in early RA are unknown. Methods: Patients with early RA (symptom duration <1 year) enrolled in the Canadian Early Arthritis Cohort who initiated disease‐modifying antirheumatic drugs and had completed HAQ data at baseline and 1 year were included in the study. Discrete‐time proportional hazards models were used to estimate crude and multi‐adjusted associations of baseline HAQ and HAQ at 1 year with all‐cause mortality in each year of follow‐up. Results: A total of 1,724 patients with early RA were included. The mean age was 55 years, and 72% were women. Over 10 years, 62 deaths (3.6%) were recorded. Deceased patients had higher HAQ scores at baseline (mean ± SD 1.2 ± 0.7) and at 1 year (0.9 ± 0.7) than living patients (1.0 ± 0.7 and 0.5 ± 0.6, respectively; P < 0.001). Disease Activity Score in 28 joints (DAS28) was higher in deceased versus living patients at baseline (mean ± SD 5.4 ± 1.3 versus 4.9 ± 1.4) and at 1 year (mean ± SD 3.6 ± 1.4 versus 2.8 ± 1.4) (P < 0.001). Older age, male sex, lower education level, smoking, more comorbidities, higher baseline DAS28, and glucocorticoid use were associated with mortality. Contrary to HAQ score at baseline, the association between all‐cause mortality and HAQ score at 1 year remained significant even after adjustment for confounders. For baseline HAQ score, the unadjusted hazard ratio (HR) was 1.46 (95% confidence interval [95% CI] 1.02–2.09), and the adjusted HR was 1.25 (95% CI 0.81–1.94). For HAQ score at 1 year, the unadjusted HR was 2.58 (95% CI 1.78–3.72), and the adjusted HR was 1.75 (95% CI 1.10–2.77). Conclusion: Our findings indicate that higher HAQ score and DAS28 at 1 year are significantly associated with all‐cause mortality in a large early RA cohort. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: A validation analysis of patients from seven countries

Author

Crowson, C.S. Gabriel, S.E. Semb, A.G. van Riel, P.L.C.M. Karpouzas, G. Dessein, P.H. Hitchon, C. Pascual-Ramos, V. Kitas, G.D. Douglas, K. Sandoo, A. Rollefstad, S. Ikdahl, E. Kvien, T.K. Arts, E. Fransen, J. Tsang, L. El-Gabalawy, H. Yáñez, I.C. Matteson, E.L. Rantapää-Dahlqvist, S. Sfikakis, P.P. Zampeli, E. Gonzalez-Gay, M. Corrales, A. van de Laar, M. Vonkeman, H. Meek, I. Husni, E. Overman, R. Colunga, I. Galarza, D. On behalf of A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis

Abstract

Objectives. Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2.Methods. Seven RA cohorts from UK, Norway, Netherlands, USA, South Africa, Canada and Mexico were combined. Data on baseline CVD risk factors, RA characteristics and CVD outcomes (including myocardial infarction, ischaemic stroke and cardiovascular death) were collected using standardized definitions. Performance of QRISK2, EULAR multiplier and ERS-RA was compared with other risk calculators [American College of Cardiology/American Heart Association (ACC/AHA), Framingham Adult Treatment Panel III Framingham risk score-Adult Treatment Panel (FRS-ATP) and Reynolds Risk Score] using c-statistics and net reclassification index. Results. Among 1796 RA patients without prior CVD [mean (s.d.) age: 54.0 (14.0) years, 74% female], 100 developed CVD events during a mean follow-up of 6.9 years (12430 person-years). Estimated CVD risk by ERS-RA [mean (s.d.) 8.8% (9.8%)] was comparable to FRS-ATP [mean (s.d.) 9.1% (8.3%)] and Reynolds [mean (s.d.) 9.2% (12.2%)], but lower than ACC/AHA [mean (s.d.) 9.8% (12.1%)]. QRISK2 substantially overestimated risk [mean (s.d.) 15.5% (13.9%)]. Discrimination was not improved for ERS-RA (c-statistic = 0.69), QRISK2 or EULAR multiplier applied to ACC/AHA compared with ACC/AHA (c-statistic = 0.72 for all) or for FRS-ATP (c-statistic = 0.75). The net reclassification index for ERS-RA was low (-0.8% vs ACC/AHA and 2.3% vs FRS-ATP).Conclusion. The QRISK2, EULAR multiplier and ERS-RA algorithms did not predict CVD risk more accurately in patients with RA than CVD risk calculators developed for the general population. © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

Published
2017

39. Reply.

Author

Fatima, Safoora, Schieir, O., Keystone, E. C., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Tin, D., Thorne, C., Bykerk, V. P., and Pope, J. E.

Subjects
FUNCTIONAL status, RHEUMATOID arthritis
Abstract

The article discusses the predictive capacity in estimating the risk of all-cause mortality among patients with Rheumatoid Arthritis (RA). Topics include HAQ disability index score, with the results showing similar levels of association with mortality but without improvement in the fit of the model; and Rheumatic Disease Comorbidity Index and could increase the rate of all-cause mortality.

Published
2022
Full Text
View/download PDF

40. Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases.

Author

Blaney, C., Sommer, J., El-Gabalawy, R., Bernstein, C., Walld, R., Hitchon, C., Bolton, J., Sareen, J., Patten, S., Singer, A., Lix, L., Katz, A., Fisk, J., and Marrie, R. A.

Subjects
PERSONALITY assessment, PERSONALITY disorders, NATALIZUMAB, DISEASES, INFLAMMATORY bowel diseases, RHEUMATOID arthritis, MENTAL health, DEMOGRAPHIC characteristics
Abstract

Aims: Although immune-mediated inflammatory diseases (IMID) are associated with multiple mental health conditions, there is a paucity of literature assessing personality disorders (PDs) in these populations. We aimed to estimate and compare the incidence of any PD in IMID and matched cohorts over time, and identify sociodemographic characteristics associated with the incidence of PD. Methods: We used population-based administrative data from Manitoba, Canada to identify persons with incident inflammatory bowel disease (IBD), multiple sclerosis (MS) and rheumatoid arthritis (RA) using validated case definitions. Unaffected controls were matched 5:1 on sex, age and region of residence. PDs were identified using hospitalisation or physician claims. We used unadjusted and covariate-adjusted negative binomial regression to compare the incidence of PDs between the IMID and matched cohorts. Results: We identified 19 572 incident cases of IMID (IBD n = 6,119, MS n = 3,514, RA n = 10 206) and 97 727 matches overall. After covariate adjustment, the IMID cohort had an increased incidence of PDs (incidence rate ratio [IRR] 1.72; 95%CI: 1.47–2.01) as compared to the matched cohort, which remained consistent over time. The incidence of PDs was similarly elevated in IBD (IRR 2.19; 95%CI: 1.69–2.84), MS (IRR 1.79; 95%CI: 1.29–2.50) and RA (IRR 1.61; 95%CI: 1.29–1.99). Lower socioeconomic status and urban residence were associated with an increased incidence of PDs, whereas mid to older adulthood (age 45–64) was associated with overall decreased incidence. In a restricted sample with 5 years of data before and after IMID diagnosis, the incidence of PDs was also elevated before IMID diagnosis among all IMID groups relative to matched controls. Conclusions: IMID are associated with an increased incidence of PDs both before and after an IMID diagnosis. These results support the relevance of shared risk factors in the co-occurrence of PDs and IMID conditions. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries

Author

Crowson, C.S., Gabriel, S.E., Semb, A.G., Riel, P.L.C.M. van, Karpouzas, G., Dessein, P.H., Hitchon, C., Pascual-Ramos, V., Kitas, G.D., Crowson, C.S., Gabriel, S.E., Semb, A.G., Riel, P.L.C.M. van, Karpouzas, G., Dessein, P.H., Hitchon, C., Pascual-Ramos, V., and Kitas, G.D.

Abstract

Item does not contain fulltext, Objectives: Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2. Methods: Seven RA cohorts from UK, Norway, Netherlands, USA, South Africa, Canada and Mexico were combined. Data on baseline CVD risk factors, RA characteristics and CVD outcomes (including myocardial infarction, ischaemic stroke and cardiovascular death) were collected using standardized definitions. Performance of QRISK2, EULAR multiplier and ERS-RA was compared with other risk calculators [American College of Cardiology/American Heart Association (ACC/AHA), Framingham Adult Treatment Panel III Framingham risk score-Adult Treatment Panel (FRS-ATP) and Reynolds Risk Score] using c-statistics and net reclassification index. Results: Among 1796 RA patients without prior CVD [mean ( s . d .) age: 54.0 (14.0) years, 74% female], 100 developed CVD events during a mean follow-up of 6.9 years (12430 person-years). Estimated CVD risk by ERS-RA [mean ( s . d .) 8.8% (9.8%)] was comparable to FRS-ATP [mean ( s . d .) 9.1% (8.3%)] and Reynolds [mean ( s . d .) 9.2% (12.2%)], but lower than ACC/AHA [mean ( s . d .) 9.8% (12.1%)]. QRISK2 substantially overestimated risk [mean ( s . d .) 15.5% (13.9%)]. Discrimination was not improved for ERS-RA (c-statistic = 0.69), QRISK2 or EULAR multiplier applied to ACC/AHA compared with ACC/AHA (c-statistic = 0.72 for all) or for FRS-ATP (c-statistic = 0.75). The net reclassification index for ERS-RA was low (-0.8% vs ACC/AHA and 2.3% vs FRS-ATP). Conclusion: The QRISK2, EULAR multiplier and ERS-RA algorithms did not predict CVD risk more accurately in patients with RA than CVD risk calculators developed for the general population.

Published
2017

45. OP0192 Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission:results from the biodam cohort

Author

Sepriano, A, Ramiro, S, Landewé, R, Heijde, D Van Der, Ohrndorf, S, Fitzgerald, O, Backhaus, M, Larché, M, Homik, J, Saraux, A, Hammer, H, Terslev, L, Østergaard, M, Burmester, G, Combe, B, Dougados, M, Hitchon, C, Boire, G, Dadashova, R, Paschke, J, Hutchings, E, Maksymowych, W, Sepriano, A, Ramiro, S, Landewé, R, Heijde, D Van Der, Ohrndorf, S, Fitzgerald, O, Backhaus, M, Larché, M, Homik, J, Saraux, A, Hammer, H, Terslev, L, Østergaard, M, Burmester, G, Combe, B, Dougados, M, Hitchon, C, Boire, G, Dadashova, R, Paschke, J, Hutchings, E, and Maksymowych, W

Published
2017

48. OP0192 Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission: results from the biodam cohort

Author

Sepriano, A, primary, Ramiro, S, additional, Landewé, R, additional, Heijde, D van der, additional, Ohrndorf, S, additional, FitzGerald, O, additional, Backhaus, M, additional, Larché, M, additional, Homik, J, additional, Saraux, A, additional, Hammer, H, additional, Terslev, L, additional, Østergaard, M, additional, Burmester, G, additional, Combe, B, additional, Dougados, M, additional, Hitchon, C, additional, Boire, G, additional, Dadashova, R, additional, Paschke, J, additional, Hutchings, E, additional, and Maksymowych, W, additional

Published
2017
Full Text
View/download PDF

50. Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis.

Author

Kuriya, B., Schieir, O., Valois, M. F., Pope, J. E., Boire, G., Bessette, L., Hazlewood, G., Thorne, J. C., Tin, D., Hitchon, C., Bartlett, S., Keystone, E. C., Bykerk, V. P., and Barra, L.

Abstract

Objective: Metabolic syndrome (MetS) prevalence in early rheumatoid arthritis (ERA) is conflicting. The impact of sex, including menopause, has not been described. We estimated the prevalence and factors associated with MetS in men and women with ERA. Methods: A cross‐sectional study of the Canadian Early Arthritis Cohort (CATCH) was performed. Participants with baseline data to estimate key MetS components were included. Sex‐stratified logistic regression identified baseline variables associated with MetS. Results: The sample included 1543 participants; 71% were female and the mean age was 54 (SD 15) years. MetS prevalence was higher in men 188 (42%) than women 288 (26%, P < 0.0001) and increased with age. Frequent MetS components in men were hypertension (62%), impaired glucose tolerance (IGT, 40%), obesity (36%), and low high‐density lipoprotein cholesterol (36%). Postmenopausal women had greater frequency of hypertension (65%), IGT (32%), and high triglycerides (21%) compared with premenopausal women (P < 0.001). In multivariate analysis, MetS was negatively associated with seropositivity and pulmonary disease in men. Increasing age was associated with MetS in women. In postmenopausal women, corticosteroid use was associated with MetS. Psychiatric comorbidity was associated with MetS in premenopausal women. MetS status was not explained by disease activity or core RA measures. Conclusion: The characteristics and associations of MetS differed in men and women with ERA. Sex differences, including postmenopausal status, should be considered in comorbidity screening. With this knowledge, the interplay of MetS, sex, and RA therapeutic response on cardiovascular outcomes should be investigated. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results